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Abstract
Purpose To compare choroidal, foveal, and
peripapillary retinal thickness between
patients with acromegaly and healthy adults.
Methods This prospective, cross-sectional,
and comparative study included 30 patients
with acromegaly (study group) and 30
healthy subjects (control group). The
subfoveal choroidal thickness (SFCT), foveal
thickness, and peripapillary retinal nerve
fibre layer thickness were measured with
spectral domain optical coherence
tomography.
Results The mean SFCT in the study group
and in the control eyes was 374.4±98.1 and
308.6±77.3 mm, respectively (Po0.001). The
mean thinnest foveal thickness value was
233.2±22.4 mm in the acromegaly group and
222.8±13.9 mm in the control group
(P¼ 0.003). The mean peripapillary retinal
nerve fibre layer thickness did not differ
significantly between the groups (P¼ 0.34).
Conclusion The SFCT and foveal thickness
were significantly higher in patients with
acromegaly, whereas peripapillary retinal
nerve fibre layer thickness was similar
between the groups.
Eye (2014) 28, 1350–1354; doi:10.1038/eye.2014.216;
published online 19 September 2014
Introduction
Acromegaly is a rare chronic disease
characterised by hypersecretion of growth
hormone and insulin-like growth factor 1
(IGF-1) predominantly due to a benign pituitary
adenoma.1,2 The annual incidence of acromegaly
is B3–4 cases per million,2,3 and it most
commonly affects middle-aged adults.4 Coarse
facial features, large joint arthropathy, skin
thickening, sleep apnoea, cardiac hypertrophy,
peripheral paresthesias, goiter, insulin resistance,
and diabetes mellitus are some of the disorders
related with acromegaly.1,5
The ocular structures and physiology are also
affected by acromegaly. Increased corneal
thickness, pigmentary degeneration of the
retina, melanocytic tumours of the choroid,
enlarged extraocular muscles, proptosis, and
total ophthalmoplegia are some of the ocular
manifestations of acromegaly.6–11 On the other
hand, there is a gap in the literature about the
impact of acromegaly on the fovea, optic nerve
head, and choroid.
In this study, our aim was to evaluate the
chorio-retinal thickness in acromegaly patients.
We hypothesized that the choroid might be
affected owing to increased risk of choroidal
tumours or cardiovascular diseases,
peripapillary retinal nerve fibre layer (RNFL)
might be affected owing to optic nerve
compression by enlarged extraocular muscles or
sleep apnoea, and fovea might be affected
owing to the diabetic features of acromegaly.
Materials and methods
In this prospective, cross-sectional, and
comparative study, a total of 60 participants (30
patients in acromegaly group and 30 healthy
adults in control group) were recruited. This
study was conducted in accordance with the
ethical standards of the Declaration of Helsinki
and was approved by the Institutional Ethical
Committee.
Study population
The study group consisted of 30 unrelated
acromegaly patients who were treated at the
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University. The diagnosis of acromegaly was made on
the basis of the criteria proposed by Freda12 and
confirmed by examination of surgically resected tissues.
Twenty-seven patients had macroadenoma, while three
of them had microadenoma. Twenty-nine patients
underwent adenomectomy by transsphenoidal route and
one patient refused surgery. All patients had been on
treatment with somatostatin analogue lanreotide autogel
at the dose of 60–120 mg i.m. every 28 days and
octreotide-LAR at the dose of 10–40 mg i.m., also every 28
days. After chronic somatostatin analogue monotherapy,
cabergoline was added if IGF-1 levels were not within
the age-adjusted normal range. Exclusion criteria were
any ocular surgery and any ocular disease other than
age-related cataract or mild refractive errors.
Ocular examination techniques
Both of the eyes of each subject were included, since
acromegaly has the potential to affect the eyes
nonidentically.10,13–15 Visual acuity levels (LogMAR),
refractive errors (diopters), intraocular pressure, and
retinal vascular caliber measurements were recorded for
all the participants. Subfoveal choroidal thickness
(SFCT), central foveal thickness, and peripapillary RNFL
values were analysed by spectral domain optical
coherence tomography (OCT) (Spectralis, Heidelberg
Engineering, Heidelberg, Germany). Choroidal thickness
was measured from the outer part of the hyper-reflective
line corresponding to the retina pigment epithelium to
the inner surface of the sclera (Figure 1). For macula
analysis, only thinnest foveal thickness was assessed. For
peripapillary RNFL analysis, the thicknesses of all the
quadrants (superior, inferior, temporal and nasal) were
recorded separately. Retinal vessel caliber measurements
were taken by using manual caliber tools provided by the
Spectralis software on the peripapillary RNFL analysis
screen. For retinal vessel caliber analysis, the three largest
retinal arterioles and venules passing through an area
one-half to one-disc diameter from the optic disc margin
were measured (Figure 2).
Statistical analysis
For statistical analysis, SPSS 17.0 software for Windows
(SPSS Inc., Chicago, IL, USA) was used to analyse
outcomes. ‘P’ values o0.05 were considered to be
statistically significant. Independent-samples t test was
used for comparison of the studied parameters between
the study group and the control group.
Results
Sixty eyes of thirty acromegaly patients and sixty eyes of
thirty healthy volunteers were examined and compared.
The mean age of the acromegaly patients was 48.4±11.9
years and the mean age of the control group was
49.2±10.5 years (P¼ 0.78). There were17 male
participants (57%) and 13 female participants (43%) in
both the acromegaly and control groups. Some of the
clinical data are presented in Table 1.
The mean time from diagnosis to the start of treatment
(surgery or medication) was 50.3±19.8 days for the
study group. The mean time from the start of treatment
to the ocular examinations was 6.9±6.1 years. There
were no significant correlations between time on
treatment and retina–choroidal thickness measurements
(Figure 3).
The mean thinnest foveal thickness value was
233.2±22.4 mm in the acromegaly group and
222.8±13.9 mm in the control group (P¼ 0.003). The mean
SFCT was 374.4±98.1 mm in the acromegaly group and
308.6±77.3 mm in the control group (Po0.001). The SFCT
Figure 2 The retinal arteriolar and venular caliber measure-
ment screen.
Figure 1 The method for measurement of choroidal thickness.
The white arrows indicate the inner surface of the sclera.
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values of acromegaly patients were B21% thicker than
that of the control group.
Mean peripapillary RNFL thickness was
101.1±14.2 mm in the acromegaly group and
103.2±8.5 mm in the control group (P¼ 0.34). The
segmental mean peripapillary RNFL thickness (inferior,
superior, nasal, and temporal quadrants) measurements
are shown in Table 2. All of the segmental RNFL
thickness values were similar between the groups.
Discussion
Growth factors have been demonstrated in the vitreous
and retina, in which they aid regulating retinal
function.16,17 Acromegaly, as a disorder characterised by
excess growth factors, might influence the retina, and so
the choroid. It was reported that IGF-I might give rise to
mild retinal oedema due to increased capillary
permeability.18 Our results quite support the previous
reports and show that acromegaly is associated with
increased foveal and choroidal thickness. Additionally,
we found that retinal vascular caliber measurements are
similar between acromegaly patients and healthy
controls.
Researches related to choroidal thickness have been
increasing recently owing to the development of
enhanced depth OCT. Nevertheless, the determinants of
choroidal thickness are not fully understood. In the
present study, we found that SFCT values were markedly
higher in acromegaly patients. This result might be due
to the vascular effects of growth factors, including
increased permeability.18 Also, there is an association
between choroidal tumours and acromegaly,8 and this
situation might be related to the higher SFCT in
acromegaly.
The mammalian retina contains IGF-I and its receptors,
in a different organization from other tissues, and have a
special distribution within the retina.19 Also, treatment
with IGF-1 causes mild, generalized, and reversible
retinal oedema.18 Harvey et al16 reported that growth
hormone is present in the human retina and vitreous
fluid, and might have a role in some of the ocular
disorders. In this study, we found that the fovea was
significantly thicker in acromegaly patients. On the other
hand, Polat et al20 found that central retinal thickness
values of acromegaly patients and control subjects were
similar. The reason for different outcomes in these
studies may be due to performing different measurement
techniques for retinal thickness, because we measured
the thinnest foveal thickness rather than areal central
macular thickness.
Growth factors have become associated with various
events of retinal disorders and optic nerve damage.21,22
Optic nerve and peripapillary RNFL damage could occur
in acromegaly owing to the compression of pituitary
adenoma on optic chiasm,4 optic nerve compression by
enlarged retrobulbar tissues,9 increased risk of sleep
apnea,5 systemic hypertension,5 and papilloedema.23
Nevertheless, in our study, there was no significant
difference between acromegaly and controls, with
respect to peripapillary RNFL thickness. Related to this
finding, it was reported that acromegaly is not associated
with increased intraocular pressure.6
Table 1 Certain clinical characteristics of the patients
Acromegaly Control P-value
VA (LogMAR) 0.015±0.047 0.003±0.018 0.06
Refraction (SE) 0.43±0.95 0.35±0.63 0.58
IOP (mm Hg) 14.1±2.2 14.1±2.6 0.96
RAC (mm) 91.2±7.1 91.1±6.3 0.90
RVC (mm) 120.9±10.9 119.3±8.5 0.38
Abbreviations: IOP, intraocular pressure; RAC, retinal arteriolar caliber;
RVC, retinal venular caliber; SE, spherical equivalent; VA, visual acuity.
Figure 3 Scatter dot graphics showing the correlations between time on treatment and retina–choroidal thickness measurements.
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Our study has several limitations. First, there was a
relatively less number of patients, but it should be
remembered that acromegaly is a very rare disease.
Second, we evaluated the patients during inactive
disease status (disease under control), because all of them
were taking medications for growth hormone inhibition.
Finally, we did not have the opportunity to evaluate
vitreal and retinal growth factor levels.
In conclusion, choroidal and foveal thickness values
were higher in acromegaly patients, when compared
with age- and gender-matched healthy subjects. On the
other hand, peripapillary RNFL values were similar
between the groups. These results might support the
opinion that acromegaly is associated with ocular
vascular permeability increase. Further studies including
choroidal blood flow measurements, whole macular
thickness analysis, fluorescein, and indocyanine green
angiography might provide better understanding about
the influence of acromegaly, and thus growth hormones,
on the retina and choroid.
Summary
What was known before
K The ocular structures, especially cornea and extraocular
muscles, are affected in acromegaly.
What this study adds
K The choroid and fovea are also affected in acromegaly
patients.
K Although, it is likely to find thinner peripapillary RNFL
in acromegaly patients, in this study, they did not differ
significantly from healthy controls.
K Retinal vascular caliber measurements are similar in
acromegaly patients and healthy controls.
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